Skip links

Category: Analytics

Covid vaccine

Covid Vaccine- How close are we?

Covid Vaccine: Why did the need arise? In December 2019, reports flocked out of central city in Wuhan, China that a new coronavirus is causing a cluster of pneumonia cases in the city. On March 11, 2020, WHO declared the coronavirus as a pandemic and

ASCO Webinar Summary: Gastric Cancer

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01) ( ) Author, Company: Kohei Shitara, MD Abstract Number: 4513 Indications: Advanced HER2+ gastric or gastroesophageal junctional adenocarcinoma Interventions: Enhertu (Trastuzumab deruxtecan) Background and

ASCO Webinar Summary: Pancreatic Cancer-II

Pharmacokinetically-guided 5-FU dose optimization within the preoperative folfoxiri regimen in resectable pancreatic cancer patients  (Link to full article)  Author, Company : Anna Vilalta, University of Navarra, Pamplona, Spain and others Abstract Number: 4636 Indications : resectable pancreatic cancer (PC) Interventions : 5-FU, folfoxiri Background and objectives: Patients having

ASCO Webinar Summary: Breast Cancer

KEYNOTE-355: A Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs. placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer ( Author, Company: Javier Cortes, MD, PhD Abstract Number: 1000 Indications: Triple Negative Breast Cancer Interventions: Pembrolizumab plus chemotherapy Background and objectives:

Convalescent plasma: A promising old therapeutic approach

Coronavirus disease 2019 (COVID-19), an acute respiratory disease whose outbreak has been declared a pandemic, infected more than 1.2 million people worldwide, killed 69,498 and 2,65,883 were recovered (as of Apr 6, 2020).1 Any approved vaccines or therapies for COVID-19? As of now, there are

Analytics – an integral part of the pharmaceutical spectrum

“Applying big-data strategies to better inform decision making could generate up to $100 billion in value annually across the US health-care system, by optimizing innovation, improving the efficiency of research and clinical trials, and building new tools for physicians, consumers, insurers, and regulators to meet

Evolution of the global regulatory scenario

Role of regulation and regulatory authorities: The entire healthcare ecosystem, from research to sales, is stringently regulated by governing authorities. These authorities include a number of local government regulatory agencies which ensure compliance in various legal and regulatory aspects of a drug. These agencies issue

Countries that will drive the global pharma market

The global pharma industry, in terms of worldwide prescription drug sales, is estimated to grow at ~6% CAGR and reach >$1 trillion in 2024. This is expected to be mainly driven by novel therapies, mainly biologics, in oncology, orphan drugs and gene therapy. Geographically, USA

“Cost-effective” innovations to drive the global pharma market

The healthcare ecosystem is a complex network of multiple industries and organizations, all of which form an intertwined web of interdependencies. The industry, in terms of worldwide prescription drug sales, is estimated to grow at ~6% CAGR and reach >$1 trillion in 2024. There are some key
Call Now Button 
Contact Us